Exchange Capital Management Inc. Sells 191 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Exchange Capital Management Inc. lessened its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 0.7% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 27,202 shares of the medical equipment provider’s stock after selling 191 shares during the quarter. Exchange Capital Management Inc.’s holdings in Zimmer Biomet were worth $2,873,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Brown Financial Advisors increased its stake in Zimmer Biomet by 3.4% in the fourth quarter. Brown Financial Advisors now owns 9,887 shares of the medical equipment provider’s stock worth $1,044,000 after purchasing an additional 321 shares during the period. Skylands Capital LLC raised its stake in Zimmer Biomet by 87.5% in the 4th quarter. Skylands Capital LLC now owns 6,986 shares of the medical equipment provider’s stock worth $738,000 after acquiring an additional 3,261 shares during the last quarter. New World Advisors LLC lifted its position in Zimmer Biomet by 7.3% during the fourth quarter. New World Advisors LLC now owns 3,813 shares of the medical equipment provider’s stock valued at $403,000 after purchasing an additional 260 shares during the period. South Dakota Investment Council grew its stake in shares of Zimmer Biomet by 266.6% during the 4th quarter. South Dakota Investment Council now owns 80,886 shares of the medical equipment provider’s stock worth $8,544,000 after purchasing an additional 58,820 shares during the period. Finally, World Equity Group Inc. acquired a new position in shares of Zimmer Biomet during the 4th quarter worth approximately $256,000. 88.89% of the stock is currently owned by institutional investors.

Zimmer Biomet Price Performance

ZBH stock opened at $106.00 on Tuesday. Zimmer Biomet Holdings, Inc. has a 52-week low of $97.69 and a 52-week high of $133.90. The stock’s fifty day simple moving average is $105.85 and its 200-day simple moving average is $107.44. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $21.10 billion, a price-to-earnings ratio of 23.82, a price-to-earnings-growth ratio of 1.95 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period last year, the firm earned $2.20 EPS. Equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Monday, December 30th were issued a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.91%. The ex-dividend date of this dividend was Monday, December 30th. Zimmer Biomet’s dividend payout ratio is currently 21.57%.

Analyst Upgrades and Downgrades

ZBH has been the subject of several research reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Raymond James cut their price target on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. Barclays decreased their price target on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a report on Monday, February 10th. Royal Bank of Canada decreased their target price on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Finally, Wells Fargo & Company increased their price objective on Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, Zimmer Biomet presently has a consensus rating of “Hold” and a consensus price target of $124.15.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.